Covance Blog
Immunotoxicology assessment plays a large role in the drug development pipeline, especially for large molecules and biologics. Researchers in early drug development have a wide variety of immunologic assay methods available that can support research endpoints and offer opportunities for much clearer views into the efficacy and safety of a …
As the COVID-19 pandemic impacted many clinical trials, sponsors were forced to quickly re-evaluate potential solutions to mitigate risks and keep trial participants safe. Continuing trials in Idiopathic Pulmonary Fibrosis (IPF) research was especially difficult as patients living with chronic lung diseases may face a greater likelihood of complications if …
The Relative Potency Assay for a typical biologic is usually the most complex assay in the release and stability specification. Relative Potency methods should be designed to be as simple as possible but should still reflect the mechanism of action (MOA) that is linked to the relevant biological properties of …
Welcome to the January 2021 edition of the Covance by Labcorp DCT blog. What’s Next? In the aftermath of a turbulent 2020, in which the overall industry perception of the decentralized clinical trial (DCT) approach transitioned from being “promising but still largely experimental” to “a new-normal paradigm for the industry …
As the volume of multiple myeloma clinical trials continues to grow, additional tests are being validated in an effort to benefit patients who typically have a five-year survival rate. These dynamics are driving strategies to address variability in testing procedures and data analysis. We recently met with the Covance dedicated …
Despite advances in treatment options, multiple myeloma incidence rates have increased since 1990. Drug development for this complex disease requires a unique combination of technology and expertise. In this short series of blog posts, Covance will share perspectives on multiple myeloma testing, technique and innovation that can reduce variability and …
The revised EU GFL (Reg (EC) 2019/1381), or transparency regulation, comes into force on 27 March 2021 and sees changes in the notification of studies, submission of dossiers via IUCLID and the publication of all study reports, to name a few. Read on to find out how these changes may …
Three specialists – Dr. Sarah Blagden, Associate Professor of Medical Oncology, University of Oxford; Maria Prendes, Head of Oncology at the Covance Biomarker Solution Center; and Kamal Saini, Senior Medical Director of Oncology at Covance – recently discussed this highly relevant topic in an educational webinar, which is now available …
Evaluating your product beyond standard characterization can provide a comprehensive understanding of a molecule in early phase development. Allan Watkinson, PhD, Director of Biopharmaceutical Development CMC at Covance, recently discussed a few of the assays that can help drug development sponsors gain new insights about their product and making earlier …
As biologics-based therapies have expanded, LC-MS is increasingly applied to support quantitative bioanalysis to detect diverse peptides and proteins. LC-MS can offer a few notable advantages compared to the traditional approach for quantification with ligand-binding assays (LBAs), but is typically thought of as a complementary approach.
